Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 9:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 635 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes in Adults Clear all
Completed Phase 2 Interventional Results available

Feasibility Study of Finesse for Bolus Prandial Insulin Dosing Compared to Multiple Daily Injections

NCT01073566
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Finesse, Pen/Syringe (Usual injection device)
Device
Lead sponsor
Calibra Medical, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
5
States / cities
San Francisco, California • Chicago, Illinois • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 3, 2026, 9:02 PM EDT
Active, not recruiting Not applicable Interventional

The Effect of Clinic Visit Audio Recordings for Self-management in Older Adults

NCT05824572
View directory record Official record
Conditions
Diabetes
Interventions
Clinic visit audio recordings for self-management in older adults, Usual Care
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
65 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Manchester, New Hampshire • Nashville, Tennessee • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 3, 2026, 9:02 PM EDT
Active, not recruiting Not applicable Interventional

Adapting FAMS to Optimize CGM Use Among Emerging Adults With Type 1 Diabetes

NCT05854069
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
FAMS-T1D, Digital resources for diabetes
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 24 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 3, 2026, 9:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Anti-Tac for Treatment of Leukemia

NCT00001941
View directory record Official record
Conditions
HTLV-I Infection, T Cell Leukemia
Interventions
daclizumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
10 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2012 · Synced Oct 3, 2026, 9:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Benefits of Eggs in Combination With a Plant-based Diet

NCT04234334
View directory record Official record
Conditions
Coronary Artery Disease, Diabetes, Metabolic Syndrome
Interventions
Consume 2 eggs with spinach per day, Egg Subsitute with spinach per day
Other
Lead sponsor
University of Connecticut
Other
Eligibility
35 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 3, 2026, 9:02 PM EDT
Completed Phase 3 Interventional Results available

A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus

NCT02302716
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2963016, LANTUS®, Oral Antihyperglycemic Medication
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Miami, Florida • New Port Richey, Florida • Smyrna, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Oct 3, 2026, 9:02 PM EDT
Completed Phase 1 Interventional

Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus

NCT01835730
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
PE0139 Injection, Placebo
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Anniston, Alabama • Hialeah, Florida • Renton, Washington
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 3, 2026, 9:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacokinetics (PK)/ Pharmacodynamics (PD) of an Extended Wear Infusion Set for Continuous Subcutaneous Insulin Infusion (CSII) in Type 1 Diabetes Mellitus (T1DM) Patients ("PEXIS")

NCT04398030
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Type 1 Diabetes
Interventions
coil-reinforced soft polymer indwelling cannula, soft Teflon indwelling catheter
Device
Lead sponsor
Capillary Biomedical, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Escondido, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Oct 3, 2026, 9:02 PM EDT
Completed Phase 2 Interventional

Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

NCT01452451
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
HM11260C, Placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Ohio City, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Oct 3, 2026, 9:02 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)

NCT05731544
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
BMF-219
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
443 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
36
States / cities
Canoga Park, California • Fountain Valley, California • La Mesa, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 3, 2026, 9:02 PM EDT
Completed Not applicable Interventional

Simplified Onboarding in Adults With Type 2 Diabetes

NCT07070830
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Active Comparator: Omnipod M System with lower starting dose, Active Comparator: Omnipod M System with higher starting dose
Device
Lead sponsor
Insulet Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 3, 2026, 9:02 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

NCT06914895
View directory record Official record
Conditions
Type 1 Diabetes, Obesity, Overweight
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
905 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
31
States / cities
Santa Barbara, California • Santa Clarita, California • Aurora, Colorado + 27 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 3, 2026, 9:02 PM EDT
Recruiting Phase 3 Interventional

KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases

NCT06451757
View directory record Official record
Conditions
Mitochondrial Diseases, Maternally Inherited Diabetes and Deafness (MIDD), Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS), Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
Interventions
Sonlicromanol, Placebo
Drug
Lead sponsor
Khondrion BV
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts • Cleveland, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 3, 2026, 9:02 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Vitamin K and Glucose Metabolism in Adults at Risk for Diabetes (Vita-K 'n' Adults Study)

NCT02366481
View directory record Official record
Conditions
Obesity, Insulin Resistance, Insulin Sensitivity, Beta-Cell Dysfunction, Prediabetes
Interventions
Placebo, Low-Dose Vitamin K2 Supplement (menaquinone-7; 90-mcg/d), High-Dose Vitamin K2 Supplement (menaquinone-7; 180-mcg/d)
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Oct 3, 2026, 9:02 PM EDT
Completed Not applicable Interventional Results available

Control-IQ Technology 2.0 Adult and Adolescent Feasibility Study

NCT05014789
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Control-IQ technology 2.0
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
14 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 3, 2026, 9:02 PM EDT
Completed Not applicable Interventional

Glucose Response in Persons with Type 2 Diabetes

NCT04914559
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Oral nutrition supplement - control, Oral nutrition supplement - test
Other
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
20 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 3, 2026, 9:02 PM EDT
Not listed Early Phase 1 Interventional

Automated SMS-Based Appointment Validation Tool

NCT01671189
View directory record Official record
Conditions
Diabetes Mellitus Type 2, Adult-onset Diabetes
Interventions
SMS Reminder Software Tool
Other
Lead sponsor
Medic Mobile
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Oct 3, 2026, 9:02 PM EDT
Recruiting Phase 2 Interventional

Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus

NCT07282743
View directory record Official record
Conditions
Type II Diabetes Mellitus
Interventions
GL0034 Dose Level 1, GL0034 Dose Level 2, GL0034 Dose Level 3, GL0034 Dose Level 4, GL0034 Dose Level 5, GL0034 Dose Level 6, Placebo
Drug · Other
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Little Rock, Arkansas • Hialeah Gardens, Florida • Lakeland, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 3, 2026, 9:02 PM EDT
Completed Phase 3 Interventional Results available

A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

NCT05872620
View directory record Official record
Conditions
Obesity, Overweight, Type 2 Diabetes
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
37
States / cities
Pelham, Alabama • Tucson, Arizona • Yuma, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 3, 2026, 9:02 PM EDT
Active, not recruiting Not applicable Interventional

Self-Management and Glycemic Control in Adult Haitian Immigrants With Type 2 Diabetes

NCT04949568
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Patient Engagement, Patient Education
Interventions
Diabetes Self-Management Behaviors
Behavioral
Lead sponsor
New York University
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 3, 2026, 9:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety of 12-weeks Supplementation of Eubacterium Hallii on Insulin Sensitivity and Glycaemic Control

NCT04529473
View directory record Official record
Conditions
Pre Diabetes, Impaired Glucose Tolerance, Insulin Sensitivity, Insulin Resistance, Glucose Metabolism Disorders, Metabolic Syndrome
Interventions
Eubacterium hallii, Placebo
Dietary Supplement · Other
Lead sponsor
Atlantia Food Clinical Trials
Industry
Eligibility
21 Years to 69 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Oct 3, 2026, 9:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Impact of Fitness and Mineralocorticoid Receptor Blockade on Vascular Dysfunction in Adults With Type 1 Diabetes

NCT03174288
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Exercise, Spironolactone
Other · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 3, 2026, 9:02 PM EDT
Completed Not applicable Interventional Results available

A Cognitive Behavioral Intervention to Reduce Fear of Hypoglycemia in Young Adults With Type 1 Diabetes

NCT03165786
View directory record Official record
Conditions
Type1diabetes
Interventions
FREE
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 30 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 3, 2026, 9:02 PM EDT
Completed Phase 1 Interventional Results available

Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 Diabetes

NCT01798264
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ITCA 650 (exenatide in DUROS)
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
30 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
Miami Gardens, Florida • Cincinnati, Ohio • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2013 · Synced Oct 3, 2026, 9:02 PM EDT